The complex role of AR signaling after cytotoxic insult - Implications for cell cycle based chemotherapeutics

被引:25
作者
Comstock, Clay E. S.
Knudsen, Karen E.
机构
[1] Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Cincinnati, OH USA
[2] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH USA
[3] Univ Cincinnati, Coll Med, Barrett Canc Ctr, Cincinnati, OH USA
关键词
prostate cancer; androgen receptor; pre-clinical; taxane; docetaxel; flavopiridol;
D O I
10.4161/cc.6.11.4353
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Prostatic adenocarcinomas are dependent on androgen receptor (AR) signaling for growth and progression, in part through the ability of AR to induce G(1)-S phase cell cycle transition. Hormonal therapies that inhibit AR activity are the first line of intervention for disseminated disease, and are initially quite effective; however, recurrent, incurable tumors ultimately arise with restored AR function. Given the importance of AR in governing the potentiation of this tumor type, there has been a dedicated interest in dissecting the mechanisms by which AR promotes prostate cancer proliferation and survival. Recent studies have challenged the utility of manipulating AR activity to enhance cell death in combination with genotoxic insult. Herein, the role of AR in controlling cell cycle progres sion and paradoxical roles of AR in survival signals are considered, as are the potential implications of these findings for chemotherapeutic response. Although there is much to be resolved, the present data suggest that knowledge of AR action in promoting cellular proliferation can be utilized for the design of coordinate strategies that maximize cell death in response to cytotoxic chemotherapeutics.
引用
收藏
页码:1307 / 1313
页数:7
相关论文
共 93 条
[21]   Role of stromal-epithelial interactions in hormonal responses [J].
Cunha, GR ;
Cooke, PS ;
Kurita, T .
ARCHIVES OF HISTOLOGY AND CYTOLOGY, 2004, 67 (05) :417-434
[22]  
Drees M, 1997, CLIN CANCER RES, V3, P273
[23]   Timing is everything: Preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer [J].
Eigl, BJC ;
Eggener, SE ;
Baybik, J ;
Ettinger, S ;
Chi, KN ;
Nelson, C ;
Wang, Z ;
Gleave, ME .
CLINICAL CANCER RESEARCH, 2005, 11 (13) :4905-4911
[24]   The development of androgen-independent prostate cancer [J].
Feldman, BJ ;
Feldman, D .
NATURE REVIEWS CANCER, 2001, 1 (01) :34-45
[25]   A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line [J].
Furutani, T ;
Takeyama, KI ;
Koutoku, H ;
Ito, S ;
Taniguchi, N ;
Suzuki, E ;
Kudoh, M ;
Shibasaki, M ;
Shikama, H ;
Kato, S .
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2005, 69 (11) :2236-2239
[26]  
Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO
[27]  
2-Q
[28]   Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland [J].
Gao, Shen ;
Wang, Hua ;
Lee, Peng ;
Melamed, Jonathan ;
Li, Caihong X. ;
Zhang, Fahao ;
Wu, Hong ;
Zhou, Liran ;
Wang, Zhengxin .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2006, 36 (03) :463-483
[29]   Chemistry and structural biology of androgen receptor [J].
Gao, WQ ;
Bohl, CE ;
Dalton, JT .
CHEMICAL REVIEWS, 2005, 105 (09) :3352-3370
[30]   Androgens regulate protein kinase Cδ transcription and modulate its apoptotic function in prostate cancer cells [J].
Gavrielides, M. Veronica ;
Gonzalez-Guerrico, Anatilde M. ;
Riobo, Natalia A. ;
Kazanietz, Marcelo G. .
CANCER RESEARCH, 2006, 66 (24) :11792-11801